• The global genomics personalized health market was valued at approximately USD 9.1 billion in 2023 and is projected to reach USD 33 billion by 2034, growing at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2034.

• North America held the largest market share in 2023, accounting for 43.84% of the global revenue, driven by advanced healthcare infrastructure and high adoption rates of genomic technologies.

• The oncology testing segment led the market in 2023, comprising 42.38% of the market share, due to the increasing prevalence of cancer and the demand for targeted therapies.

• Technological advancements, such as the development of next-generation sequencing (NGS) platforms and artificial intelligence (AI)-driven diagnostics, are enhancing the accuracy and efficiency of genomic analyses.

• The Asia-Pacific region is expected to experience the highest growth rate, with a projected CAGR of 18% during the forecast period, attributed to increasing healthcare investments and rising demand for personalized medicine.

• Key market players include Illumina, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Roche, and Lonza Group, focusing on expanding their product portfolios and strategic partnerships to strengthen their market presence.

• Government initiatives and increasing awareness about the benefits of personalized healthcare are contributing to the growth of the genomics personalized health market, encouraging the adoption of genomic testing and tailored treatments.

• In March 2025, Function Health partnered with the National Basketball Players Association to offer advanced genetic and biomarker testing to athletes and corporate employees.

• In May 2025, a new IoT-based genomics monitoring system was launched, enabling real-time tracking of key health metrics with cloud integration and alerts for timely medical intervention.

In this report, the Personalized Genomics Market has been segmented by Test Type, Technology, Application, End User and Geography.

Personalized Genomics Market Segmentation by Test Type

The Personalized Genomics Market is segmented by Test Type into Oncology Testing, Infectious Disease Testing, Neurological Testing, Cardiovascular Testing, and Others. Each testing category plays a vital role in advancing precision healthcare through early detection and targeted treatment. The market growth is driven by technological innovation, patient awareness, and a 45% surge in demand for genomic testing in clinical and research environments.

Oncology Testing

Oncology testing remains the largest segment, accounting for over 40% of market revenue. It focuses on identifying genetic mutations and optimizing targeted therapies. The integration of genomic biomarkers has accelerated personalized cancer treatment adoption across oncology centers.

Infectious Disease Testing

Infectious disease genomics aids in real-time pathogen detection and outbreak management. Growing utilization in virology and public health programs, especially post-pandemic, has resulted in a 35% increase in demand for rapid sequencing-based diagnostics.

Neurological Testing

Neurological genomics focuses on genetic profiling for disorders such as Alzheimer’s and Parkinson’s. This segment’s adoption has risen by 30% due to breakthroughs in neurogenetic research and the rise of personalized neuro-therapeutics.

Cardiovascular Testing

Cardiovascular testing uses genomic mapping to assess inherited heart risks and drug responsiveness. Integration with precision cardiology platforms has enhanced preventive care and clinical outcome prediction accuracy by nearly 42%.

Others

The Others segment includes emerging genomic tests in autoimmune, metabolic, and rare diseases. Expanding research collaborations and AI-driven analytics are accelerating this category’s market penetration.

Personalized Genomics Market Segmentation by Technology

The Technology segmentation includes PCR-Based Tests, Microarray-Based Tests, Sequencing-Based Tests, and Others. Each technology underpins advancements in genetic diagnostics and data interpretation. The rising integration of high-throughput sequencing and bioinformatics tools supports clinical precision and research scalability.

PCR-Based Tests

PCR-based testing remains a cornerstone in genomic diagnostics, with 50% penetration due to its accuracy and affordability. It continues to be widely used for infectious disease detection, genetic screening, and personalized drug monitoring.

Microarray-Based Tests

Microarray technologies enable large-scale gene expression profiling and mutation analysis. Adoption has increased by 33%, driven by applications in pharmacogenomics, oncology, and rare disease diagnostics.

Sequencing-Based Tests

Sequencing-based methods such as next-generation sequencing (NGS) have revolutionized personalized genomics, offering comprehensive DNA insights. Over 60% of major research institutions now employ sequencing for precision diagnostics and therapeutic discovery.

Others

The Others category includes CRISPR, proteomics, and metabolomics-based genomic solutions. These technologies are expanding personalized medicine applications through multi-omics data integration and advanced molecular analytics.

Personalized Genomics Market Segmentation by Application

The Application segmentation encompasses Diagnostics, Precision Medicine, Wellness, Reproductive Health, Sports Nutrition & Health, Lifestyle, and Others. Each application area enhances individual health profiling and therapeutic customization, with growing emphasis on preventive care and genomic wellness.

Diagnostics

Genomic diagnostics lead adoption with 48% of the market share, supporting early disease detection and genetic counseling. Increased integration of AI for variant interpretation is accelerating diagnostic precision.

Precision Medicine

Precision medicine applications leverage genomics for tailored treatment strategies. The segment has seen a 50% rise in usage among oncology and chronic care programs emphasizing targeted drug therapies.

Wellness

Genomic wellness testing focuses on nutrition, metabolism, and fitness optimization. Adoption has expanded by 35%, as consumers seek DNA-based health insights for preventive lifestyle planning.

Reproductive Health

Reproductive genomics drives growth through prenatal screening, carrier testing, and IVF support. Over 40% of fertility clinics now integrate genomic insights into reproductive decision-making.

Sports Nutrition & Health

Sports genomics applies personalized genetic testing for performance enhancement and injury prevention. Athlete adoption is growing by 32%, highlighting partnerships between biotech firms and sports institutes.

Lifestyle

Lifestyle genomics encompasses personalized wellness programs, skincare, and dietary genetics. The segment benefits from consumer-driven innovation and expansion in direct-to-consumer genetic testing platforms.

Others

Other applications include emerging use cases in epigenetics and longevity research. These focus areas are expected to expand rapidly, supported by integrative data analytics and precision-based health monitoring systems.

Personalized Genomics Market Segmentation by End User

The End User segmentation includes Hospitals & Clinics, Research Centers, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, and Others. Each segment demonstrates strong collaboration across research, clinical, and industrial domains to strengthen genomic infrastructure and data-driven healthcare delivery.

Hospitals & Clinics

Hospitals & clinics lead market implementation, representing 40% of demand. Integration of personalized genomic testing into patient workflows supports precision diagnostics and therapy alignment.

Research Centers

Research centers drive innovation through genomic sequencing and bioinformatics development. Collaborative projects have risen by 45%, enhancing translational research and gene-targeted drug discovery.

Pharmaceutical & Biotechnology Companies

Pharmaceutical and biotech firms leverage genomics for biomarker discovery and clinical trials. Over 50% utilize patient-specific genetic data to streamline drug development pipelines.

Diagnostic Laboratories

Diagnostic laboratories play a crucial role in processing genomic samples with high throughput capacity. Technological partnerships and automation have led to a 38% improvement in testing efficiency and scalability.

Others

The Others segment covers consumer testing companies and academic institutions. These organizations are expanding data accessibility and awareness of personalized genomic testing benefits.

Personalized Genomics Market Segmentation by Geography

In this report, the Personalized Genomics Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

North America leads the Personalized Genomics Market with over 38% share, driven by advanced healthcare infrastructure and high consumer awareness. Strategic partnerships between genomic testing firms and healthcare providers are enhancing personalized medicine accessibility.

Europe demonstrates significant progress through precision medicine initiatives and regulatory support for genetic data use. Around 33% of regional diagnostics utilize genomics, reflecting the continent’s strong research ecosystem and ethical framework.

Asia Pacific is the fastest-growing region, expanding by 45% in adoption. Government-led genomics programs and investment in biobanking are fostering innovation, particularly in China, Japan, and India.

Middle East & Africa are emerging with increasing genomics adoption across research and clinical diagnostics. Growth of 28% is supported by healthcare modernization and cross-border collaborations in precision healthcare.

Latin America is experiencing steady expansion as genomic testing becomes more accessible. Increased investment in diagnostic infrastructure and awareness of preventive healthcare are contributing to regional market acceleration.